Developing Therapeutics Against Virtually Any Target with New Antibody Libraries (Mandarin)

alt text
Presented by
Jay Yang, PhD
Business Development Manager - Biopharma, APAC, Twist Bioscience

Monoclonal antibodies have become the preferred therapeutic modality for cancer, infectious diseases, inflammatory and autoimmune disorders, and other conditions.
 
Twist Bioscience is on a mission to support this work, offering a Library of Libraries containing multiple pre-constructed and validated libraries against many high-value targets with which scientists can build a comprehensive and robust antibody discovery platform.

Watch the video  to:  

  • Learn about the Hyperimmune Library for therapeutic development against virtually any target.
  • Hear how the latest libraries are opening new sequence space, allowing researchers to focus on difficult-to-drug targets like GPCRs and ion channels.
  • Review recent work from Twist Biopharma using the Library of Libraries against human ACE2 and the SARS-CoV-2 spike protein to find potently neutralizing candidate antibodies against the SARS-CoV-2 strain of coronavirus in under 4 weeks.
  • Compare options for accessing the Library of Libraries, including licensing or partnering to fully outsource lead discovery.
Share your details to Watch the Webinar